Vaximm AG
Records under this name other than the patents Vaximm AG holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 5 patents it holds.
Showing 1 to 6 of 6 · Back to Vaximm AG
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,493,738 | Method for Producing High Yield Attenuated Salmonella Strains Formerly held In force · High confidence | In force | High confidence | |
| US 10,821,163 | Process for the production of a DNA vaccine for cancer immunotherapy Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 11,590,215 | Process for the Production of a DNA Vaccine for Cancer Immunotherapy Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 11,357,842 | PD-L1 targeting DNA vaccine for cancer immunotherapy Lapsed on the fee record Ended Jun 14, 2026 · From the USPTO record | Lapsed on the fee record | Ended Jun 14, 2026 | From the USPTO record |
| US 9,920,297 | Salmonella-Based Vectors for Cancer Immunotherapy Targeting Wilms' Tumor Gene WT1 Lapsed on the fee record Ended Mar 20, 2026 · High confidence | Lapsed on the fee record | Ended Mar 20, 2026 | High confidence |
| US 10,815,455 | Salmonella-based vectors for cancer immunotherapy targeting Wilms' tumor gene WT1 Lapsed on the fee record Ended Oct 27, 2024 · From the USPTO record | Lapsed on the fee record | Ended Oct 27, 2024 | From the USPTO record |